IP Library Granted Patent US 11,207,345
Granted Patent B2
US 11,207,345 · App. 16/896,823 · Granted Dec 28, 2021

Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease

Inventors: Sho Funayama (Tokyo, JP); Risa Nodera (Tokyo, JP); Takahiro Hatanaka (Tokyo, JP)
Assignee: SEIKAGAKU CORPORATION
A61K31/738A61K9/0048A61K9/08A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,345
App. No.
16/896,823
Granted
Dec 28, 2021
Kind
B2
Abstract

Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Claims (9)

1. A method for the treatment of a corneal epithelial disorder and/or dry eye in a subject in need thereof, the method comprising administering a composition comprising a chondroitin sulfate derivative having a cross-linked structure through a cross-linker, the derivative being cross-linked between disaccharide units of chondroitin sulfate, and a pharmaceutically acceptable carrier to at least one eye of the subject,

wherein the composition is in the form of a solution, and

wherein the composition passes through a porous filter (pore size: 5.0 μm, diameter: 25 mm) at a passing rate of 80% or more at 25° C., and

wherein the composition is administered topically to the eye.

2. The method according to claim 1 , wherein the composition serves as a dosage form, the dosage form being at least an aqueous eye drop.

3. A method for the treatment of a corneal epithelial disorder and/or dry eye in a subject in need thereof, the method comprising administering a composition comprising a chondroitin sulfate derivative having a cross-linked structure through a cross-linker, the derivative being cross-linked between disaccharide units of chondroitin sulfate, and a pharmaceutically acceptable carrier to at least one eye of the subject,

wherein the composition is in the form of an aqueous solution, and

wherein the composition passes through a porous filter (pore size: 5.0 μm, diameter: 25 mm) at a passing rate of 80% or more at 25° C., and

wherein the composition serves at least as a dosage form selected from an eye drop, an eye ointment, a cream, or a lotion.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2020
From: FUNAYAMA, SHO; NODERA, RISA; HATANAKA, TAKAHIRO
To: SEIKAGAKU CORPORATION
Reel/Frame 052889/0607 →
Priority Claims (2)
JP 2015-007072 · Jan 16, 2015 · national
JP 2015-150976 · Jul 30, 2015 · national
Continuity (3)
Continuation 16536779 · Aug 9, 2019
Continuation 15543748
Related Publication 20210052634A1 · Feb 25, 2021
Cited By (2)
US 12,310,981 US 12,440,510